These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 32226538

  • 1. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
    Zhang Z, Yao Y, Yuan Q, Lu C, Zhang X, Yuan J, Hou K, Zhang C, Du Z, Gao X, Chen X.
    Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
    [Abstract] [Full Text] [Related]

  • 2. Germacrone alleviates breast cancer-associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF-κB signaling pathways.
    Lin Z, Yang Y, Liu T, Wu Z, Zhang X, Yang J.
    Phytother Res; 2024 Jun; 38(6):2860-2874. PubMed ID: 38558446
    [Abstract] [Full Text] [Related]

  • 3. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.
    Chen Y, Zheng J, Mo L, Chen F, Li R, Wang Y, Liang Q, Chen Z, Dai W, Chen L, Yan P, Zhou H, Li X.
    Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920
    [Abstract] [Full Text] [Related]

  • 4. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
    Li Z, Xiao J, Wu X, Li W, Yang Z, Xie J, Xu L, Cai X, Lin Z, Guo W, Luo J, Liu M.
    Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
    [Abstract] [Full Text] [Related]

  • 5. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
    Jiang W, Rixiati Y, Huang H, Shi Y, Huang C, Jiao B.
    Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
    [Abstract] [Full Text] [Related]

  • 6. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
    Sung B, Oyajobi B, Aggarwal BB.
    Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419
    [Abstract] [Full Text] [Related]

  • 7. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.
    Cancer Res; 2005 Jun 01; 65(11):4929-38. PubMed ID: 15930315
    [Abstract] [Full Text] [Related]

  • 8. Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation.
    Li J, Feng W, Lu H, Wei Y, Ma S, Wei L, Liu Q, Zhao J, Wei Q, Yao J.
    J Cell Physiol; 2019 Aug 01; 234(8):12663-12675. PubMed ID: 30536376
    [Abstract] [Full Text] [Related]

  • 9. Cryoprotective isoliquiritigenin-zein phosphatidylcholine nanoparticles inhibits breast cancer-bone metastasis by targeting JAK-STAT signaling pathways.
    Ganesan K, Xu C, Xie C, Sui Y, Zheng C, Gao F, Chen J.
    Chem Biol Interact; 2024 Jun 01; 396():111037. PubMed ID: 38719172
    [Abstract] [Full Text] [Related]

  • 10. The role played by ailanthone in inhibiting bone metastasis of breast cancer by regulating tumor-bone microenvironment through the RANKL-dependent pathway.
    Wang Y, Zhong Z, Ma M, Zhao Y, Zhang C, Qian Z, Wang B.
    Front Pharmacol; 2022 Jun 01; 13():1081978. PubMed ID: 36686653
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
    Wang H, Shen W, Hu X, Zhang Y, Zhuo Y, Li T, Mei F, Li X, Xiao L, Chu T.
    Breast Cancer Res Treat; 2015 Feb 01; 149(3):705-14. PubMed ID: 25667102
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
    Kim KR, Kim HJ, Lee SK, Ma GT, Park KK, Chung WY.
    PLoS One; 2015 Feb 01; 10(4):e0122764. PubMed ID: 25859665
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling.
    Yang Q, Guo J, Zheng J, Chen Y, Zou B, Li R, Ding Z, Wang Y, Li L, Chen Z, Mo L, Liang Q, Chen F, Li X.
    Int Immunopharmacol; 2023 Jul 01; 120():110316. PubMed ID: 37253315
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling.
    Zhang Y, Zou B, Tan Y, Su J, Wang Y, Xu J, Tao L, Zhou H, Liu L, Li X.
    Pharmacol Res; 2019 Apr 01; 142():140-150. PubMed ID: 30797069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.